BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer
BioClin Therapeutics, Inc. (BioClin), a privately-held clinical stage biotechnology company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody to treat solid tumors, specifically metastatic bladder cancer, announced today the appointments of Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer. This build out of the executive team follows the closing of a $30 million Series B financing announced last year.
Dr. Currie has over 25 years of drug development experience in both pharmaceutical and biotechnology companies, having held senior leadership roles at Dynavax Technologies Corp., Regeneron Pharmaceuticals, Sepracor Inc. and PDL Biopharma.
Dr. Abella has been actively involved in cancer clinical trials research for nearly 30 years, most recently at Gilead Sciences, Inc. and Amgen, Inc.
“Graeme and Steve are tremendous additions to our team,” said Stephen Lau, Chief Executive Officer of BioClin. “Their experience in building and leading organizations, combined with their extensive work in developing and commercializing products that address important patient needs will be instrumental as we enter our next phase of growth.”
“I am thrilled to join BioClin at this important time during the company’s evolution,” said Graeme Currie, Ph.D, BioClin’s Chief Operating Officer. “Developing and implementing the clinical development strategy and planning for registrational studies for B-701 for metastatic bladder cancer is our top priority. I look forward to helping advance this important therapeutic.”
“I am excited to join this team of professionals who are scientifically driven to improve treatment options for patients,” said Steve Abella, M.D., Chief Medical Officer of BioClin. “I was impressed by the team’s expertise and energy, and I look forward to taking a leadership role in shaping BioClin’s clinical development strategy as we advance B-701 in the clinic.”
Graeme Currie was most recently Vice President of Clinical Science and Operations at Dynavax Technologies Corp. Prior to that, he spent six years at Regeneron Pharmaceuticals as the Vice President of Clinical Project Management and Operations and oversaw operations for 16 molecules and multiple therapeutic areas. During his tenure, Graeme was closely associated with the development programs for Eylea® for Wet AMD and DME, Praluent® for hypercholesterolemia and Dupixent® for Atopic Dermatitis. Prior to Regeneron, Graeme was Vice President of Clinical Operations at Sepracor Inc. and at PDL Biopharma. Graeme also spent 6 years as a Director at Gilead Sciences Inc., working in Hepatitis developing Hepsera™ for Chronic Hepatitis B. Prior to Gilead, he had roles at IPSEN Biopharmaceuticals Inc. and Glaxo Wellcome. Graeme received a BSc from the University of Salford, and a Ph.D. in Oncology from Aston University.
Esteban (Steve) Abella has been actively involved in cancer clinical trials research for nearly 30 years including most recently at Gilead Sciences Inc. At Gilead, Steve was a Senior Director leading non-hodgkin’s lymphoma and leukemia efforts, as well as serving as a core member of the oncology senior leadership team. Prior to that, he served as the Executive Director at Amgen Inc., predominately responsible for the white cell franchise (Neulasta®/Neupogen®) global development efforts across clinical research and medical affairs. His clinical experiences prior to joining industry include 15 years in academic oncology, serving as Professor of Pediatric Oncology, and Medicine at the Barbara Ann Karmanos Cancer Institute, focused on stem cell transplantation and oncology clinical trials. Steve completed his fellowship and residency training at Wayne State University School of Medicine after graduating with a degree in medicine from the Universidad Central del Este. He attended the University of Pennsylvania for undergraduate studies.
About BioClin Therapeutics, Inc.
BioClin Therapeutics, Inc. is a privately-held clinical stage biotechnology company developing biologics to address medical conditions in areas of high unmet need. The company is focused on FGFR3 (fibroblast growth factor receptor 3), a driver mutation in metastatic bladder cancer and potentially other cancers. The company’s lead program, B-701, is the only targeted biologic specific for FGFR3 in clinical development. BioClin has ongoing clinical studies in metastatic bladder cancer using multiple therapeutic approaches (as B-701 monotherapy, and in combination therapies with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor).
For more information, please visit BioClin’s website: www.bioclintherapeutics.com
BioClin Therapeutics, Inc.
Chief Executive Officer
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
AI Expo: What Not to Miss at the AI Expo Europe Next Week Including Female Expert Speakers20.6.2018 12:00 | Tiedote
Arriving in Amsterdam next week on the 27-28 June, the second annual AI Expo Europe event will be co-hosted with two co-located events covering the IoT and Blockchain ecosystem; IoT Tech Expo & Blockchain Expo. With over 9,000 top-level attendees already registered including CTO’s, CDO’s, Heads of Innovation & Technology, IT Directors, Developers, Start-Up’s, VC’s, OEM’s across a range of industries including but not limited to; Marketing, Automotive, HR & Recruitment, Finance, Insurance, Government, Public Sector, Retail, Industrial, Healthcare, Education, Cyber Security and Developer platforms. The AI Expo will showcase the most cutting-edge technologies from more than 300 exhibitors and provide insight from over 300 speakers sharing their unparalleled industry knowledge, real-life experiences, valuable case studies & dedicated Q&A sessions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180620005048/en/ Leading female AI
Alibaba Group and Kantar Join Forces to Redefine Brand Building at ‘China-Speed’20.6.2018 12:00 | Tiedote
Kantar and Alibaba Group announced today, during Cannes Lions International Festival of Creativity, the launch of their new partnership to redefine brand building in China by co-creating an integrated ‘insight to activation’ platform that will help CMOs to develop, measure and optimise their marketing activities at ‘China Speed.’ Together, they will help brands realise the vision of ‘real time’ brand and campaign management. Today, marketers of Chinese and global brands alike see their marketing strategies outpaced by the scale, scope and speed of China’s consumer market and media transformation. To address these needs, the first phase of the partnership focused on unifying fragmented brand metrics into a new integrated ‘insight-to-activation’ platform, enabling brands and businesses to make more agile decisions. Kantar mapped and validated Alibaba’s Marketing KPI ‘Consumer Asset’ framework (launched in 2017) to Kantar’s broader portfolio of marketing KPIs. With the validation of the C
Deutsche Bank Moves Reconciliation Services to SmartStream to Further Improve Processing and Reduce Costs20.6.2018 11:00 | Tiedote
As part of a wider strategy to adopt industry utilities, Deutsche Bank has selected SmartStream Technologies’ Centre of Excellence (CoE) to provide an off-site operations platform - including three services which will allow the bank to streamline, simplify and reduce the costs of its reconciliations environment. With the growth in volume of reconciliations, the processing of large quantities of data has become complex. Many financial institutions are exploring utilities to ensure accuracy and cost savings. With the addition of the CoE to Deutsche Bank, SmartStream will provide the bank with three distinct managed services: Reconciliations On-Boarding, Production Support and Operational Reconciliation Services. The new services will improve processing of reconciliations by making it faster and more cost-effective. The integration of the overall service will be done in a phased approach, where Deutsche Bank will increase productivity and reduce costs through mutualisation. SmartStream’s
AETOSWire Launches Its Innovative Press Video Service20.6.2018 10:00 | Tiedote
AETOSWire, the news distribution arm of News Services Group and the exclusive representative of Business Wire, a Berkshire Hathaway company, in the MENA region, launched the innovative Press Video Service that transforms textual press releases into a less than 60-Seconds Animated Press Video. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180620005113/en/ To keep pace with the ever-evolving and advancing communications landscape, AETOSWire always aim to anticipate the future needs of its clients and stakeholders. The Press Video is one of the latest services launched by AETOSWire along with a few most sought-after communication services, like the Audio Alerts for Journalists, to mark its 10 years in the industry. The Press Video came about as a response to the influx of press releases on various media outlets, whereby clients’ messages would get lost in the mound of press releases. With thousands of news available online, cl
Tigo Awarded Patent for Flex MLPE Platform20.6.2018 09:00 | Tiedote
Tigo®, pioneer of the Smart Modular Flex MLPE platform, today announced that it has been granted its most important and industry strategic hardware patent applying to the smart technology used in its flexible module-level power electronics (Flex MLPE) within solar junction boxes. Tigo’s connection box with reliable and inexpensive contacts for solar modules is now patented to enable the use of multiple types of passive and active covers for different functionalities in the junction box. To learn more, Tigo will be displaying its Flex MLPE during Intersolar Munich 2018 from June 20th – 22nd with multiple OEM and distribution partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180619006499/en/ The Flex MLPE's contacts within the junction box allow for high current, exposure to extreme elements, and interchangeable covers. (Photo: Business Wire) U.S. Patent 9,991,843 is Tigo’s 56th patent issued by the U.S. Patent and Trad
Ant Financial to Share Full Suite of AI Capabilities with Asset Management Companies20.6.2018 04:10 | Tiedote
Ant Financial Services Group (“Ant Financial” or “the Company”) today announced that the Company will share a full suite of AI capabilities with asset management companies in China to support their digital transformation. Following its successful launch last year, Caifuhao, an AI-powered corporate account on the Ant Fortune platform, has brought tangible benefits to 27 fund management companies. “By combining Ant Financial’s AI technologies with the capabilities of asset management companies in investor education and fund management, together we are making customized wealth management services more accessible for ordinary users,” said Eric Jing, Executive Chairman and CEO of Ant Financial. With the support of AI-powered services offered by their Caifuhao account, including operational optimization, content generation, compliance and risk management, 27 fund management companies have been able to increase their operational efficiency by 70% while reducing their overall costs by 50%. Add
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme